May 17, 2020

CIO survey reveals healthcare is lacking in THIS aspect of business

Admin
2 min
CIO survey reveals healthcare is lacking in THIS aspect of business.jpg
Although the healthcare field has been ahead of embracing the mobile health industry for some time now, the industry as a whole still fails to improve...

Although the healthcare field has been ahead of embracing the mobile health industry for some time now, the industry as a whole still fails to improve one key aspect: leveraging mobile to better engage customers and/or patients.

Recently, a survey of 2,300 chief information officers at various U.S. companies was released, and the results were less then positive in terms of how companies are working to better engage their customers. Over 70 percent of CIOs reported that they had some kind of mobile strategy for interacting with customers, but most of those came in at 56 percent, saying that they have both native apps and mobile-friendly websites.

The survey was conducted by Robert Half Technology, and the findings went on to demonstrates that a percentage of CIOs at healthcare companies had no mobile strategy at all, compared to others from various disciplines. A total of 36 percent of CIOS at healthcare companies reported having no strategy at all, where 60 percent of CIOs from business and retail companies said they employ both apps and mobile-friendly websites in their business ventures.

“To maintain competitive advantage, sectors such as business services and retail need to connect with customers anytime, anywhere, so it’s logical to see them leading the charge in implementing mobile strategies,” John Reed, Senior Executive Director, Robert Half Technology said in a statement. “Compliance issues have made it difficult for the healthcare industry to move as quickly as other sectors, but as consumer demand for mobile health information grows, formal mobile strategies are a necessary next step.”

Last year, a different study was conducted to measure 100 healthcare CIOS and other health IT professionals to evaluate provider settings. The study found that 17 percent believed that mobile health would have a more significant impact on healthcare than either integrated healthcare facilities or the inclusion of EHR technology.

So, what do all these numbers mean in the short-term and long-term goals? Healthcare companies need to spend equal time investing in mobile health initiatives, and employing better means of accessibility to these heavily-invested in ideas. Without access to these create healthcare apps, how will the public benefit from them? 

Share article

Aug 4, 2021

C. Light aim to detect Alzheimer's with AI and eye movements

alzheimers
AI
Technology
healthcare
3 min
C. Light aim to detect Alzheimer's with AI and eye movements
C. Light Technologies will use AI to study eye movements and monitor the progression of Alzheimer's

 C. Light Technologies, a neurotechnology and AI company based in Boston, has received funding for a pilot study that will assess changes in eye motion during the earliest stage of Alzheimer's, known as mild cognitive impairment. 

C. Light Technologies has partnered with the UCSF Memory and Aging Center for this research. As new therapeutics for Alzheimer’s are introduced to the clinic, this UCSF technology has the potential to provide clinicians a better method to measure disease progression, and ultimately therapeutic efficacy, using C. Light’s novel retinal motion technology.

Eye motion has been used for decades to triage brain health, which is why  doctors asks you to “follow my finger” when they want to assess whether you have concussion. In more than 30 years of research, studies have revealed that Alzheimer’s disease patients' eye movements are affected by the disease, though to date, these eye movements have only been measured on a larger scale.

C. Light’s research takes the eye movement tests to a microscopic level for earlier assessments. Clinicians can study and measure eye motion on a scale as small as 1/100th the size of a human hair, which can help them monitor a patient’s disease and treat it more effectively.

The tests are also easy to administer. Patients put their chin in a chinrest and  focus on a target for 10 seconds. The test does not require eye dilation, and patients are permitted to blink. A very low-level laser light is shown through the pupil and reflects off the patient’s retina, while a sensitive camera records the cellular-level motion in a high-resolution video. This eye motion is then  fed into C. Light’s advanced analytical platform.

“C. Light is creating an entirely new data stream about the status of brain health via the eye,” explains Dr. Christy K. Sheehy, co-founder of C. Light.  “Our growing databases and accompanying AI can change the way we monitor and treat neurological disease for future generations. Ultimately, we’re working to increase the longevity and quality of life for our loved ones." 

At the moment developing therapeutic treatments for the central nervous system is difficult, with success rates of only 8% to go from conception to market. One reason for this is the lack of tools to measure the progression of diseases that impact the nervous system. 

Additionally clinical trials can take a decade to come to fruition because the methods used to assess drug efficacy are inefficient. C. Light believe they can change this. 

“Before this year, it had been almost 20 years since an Alzheimer’s drug was brought to market" explains Sheehy. "Part of the reason for this very slow progress is that drug developers haven’t had viable biomarkers that they can use to effectively stratify patients and track disease on a fine scale. The ADDF’s investment will allow us to do that." 

C. Light has received the investment from the Alzheimer’s Drug Discovery Foundation (ADDF) through its Diagnostics Accelerator, a collaborative research initiative supported by Bill Gates, the Dolby family, and Jeff Bezos among other donors. 

C. Light recently completed its second and final seed round raising $500,000, including the ADDF investment, which brings their total seed funding to more than $3 million. Second round seed funders included: ADDF, the Wisconsin River Business Angels, Abraham Investments, LLC and others.
The ADDF’s Diagnostics Accelerator has made previous investments in more than two dozen world-class research programmes to explore blood, ocular, and genetic biomarkers, as well as technology-based biomarkers to identify the early, subtle changes that happen in people with Alzheimer’s. 

Share article